Astrazeneca (AZN) Cash & Current Investments (2009 - 2026)

Astrazeneca's Cash & Current Investments history runs 18 years deep, the most recent figure standing at $7.9 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 45.99% year-over-year to $7.9 billion; the TTM figure through Mar 2026 stood at $7.9 billion (up 45.99% YoY), while the FY2025 annual figure was $6.2 billion, up 12.38% from the prior year.
• Cash & Current Investments was $7.9 billion for Q1 2026 at Astrazeneca, up from $6.2 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $8.6 billion in Q3 2025 to a low of $1.3 billion in Q4 2024.
• Historically, Cash & Current Investments has averaged $6.0 billion across 5 years, with a median of $6.0 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments slumped 78.98% in 2024, then soared 395.93% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $6.3 billion in 2022, then decreased by 4.75% to $6.0 billion in 2023, then plunged by 78.98% to $1.3 billion in 2024, then jumped by 395.93% to $6.2 billion in 2025, then grew by 27.91% to $7.9 billion in 2026.
• The last three Cash & Current Investments figures came in at $7.9 billion (Q1 2026), $6.2 billion (Q4 2025), and $8.6 billion (Q3 2025), per Business Quant data.